<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769427</url>
  </required_header>
  <id_info>
    <org_study_id>PDO-122020</org_study_id>
    <nct_id>NCT04769427</nct_id>
  </id_info>
  <brief_title>Non-Surgical Rhinoplasty Using PDO Threads</brief_title>
  <official_title>Non-Surgical Rhinoplasty Using Polydioxanone Threads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical revision&#xD;
      rhinoplasty on first impressions and quality of life (FACE-Q scale) in 10 patients who desire&#xD;
      further changes to their nasal tip and/or nasal dorsum&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Actual">October 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non -surgical rhinoplasty using PDO Max threads</measure>
    <time_frame>1 month</time_frame>
    <description>The effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale). FACE-Q scales are rated from 1-4 with ratings closer to 4 as more favorable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non -surgical rhinoplasty using PDO Max threads</measure>
    <time_frame>1 month</time_frame>
    <description>The effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on first impressions (using the first impression questionnaire). Questionnaire is rated from 1 to 10 with results closer to 10 as more favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non -surgical rhinoplasty using PDO Max threads</measure>
    <time_frame>1 month</time_frame>
    <description>The efficacy in reduction of nasal dorsum convexity, and improvement of tip rotation and projection as measured on pre/post injection 2D photographs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Nasal Defect</condition>
  <arm_group>
    <arm_group_label>PDO Max thread injection to nose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PDO max threads</intervention_name>
    <description>To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)</description>
    <arm_group_label>PDO Max thread injection to nose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females of ages 18 and above.&#xD;
&#xD;
          2. Subjects will be required not to have had previous filler injections, or other&#xD;
             cosmetic treatments to the nose within the last 12 months.&#xD;
&#xD;
          3. Subjects that understand the purpose and aspects of the study, freely sign the consent&#xD;
             and complete the required treatment and follow up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Males and females below age of 18.&#xD;
&#xD;
          2. Subjects who have had previous surgery, filler injections, or other cosmetic&#xD;
             treatments to the nose within the last 12 months.&#xD;
&#xD;
          3. Patients with any prior nasal implants&#xD;
&#xD;
          4. Subjects who are pregnant or nursing.&#xD;
&#xD;
          5. Subjects with a known allergy or sensitivity to any component of the study&#xD;
             ingredients.&#xD;
&#xD;
          6. Any history of bleeding disorders (iatrogenic or otherwise). This includes persons who&#xD;
             have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet&#xD;
             aggregation in the preceding 3 weeks.&#xD;
&#xD;
          7. Anyone taking aspirin, ibuprofen, St. John's Wort, or high doses of Vitamin E&#xD;
             supplements in the last 3 weeks.&#xD;
&#xD;
          8. Subjects with diseases, injuries, or disabilities of the nose, including those with&#xD;
             autoimmune disease affecting the nose&#xD;
&#xD;
          9. Subjects that do not understand the purpose and aspects of the study, do not sign the&#xD;
             consent and do not complete the required treatment and follow up visit will also be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

